Short answer
TG THERAPEUTICS, INC. (TGTX) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $240M (up 70.3% year over year) with net income of $8M.
Q2 2026 key financials · XBRL
- Revenue
- $240M
- +70.3% YoY · +17.3% QoQ
- Net income
- $8M
- −72.4% YoY · −60.7% QoQ
- Operating margin
- 9.0%
- EPS (diluted)
- $0.05
- −70.6% YoY · −58.3% QoQ
Source: XBRL data from the TG THERAPEUTICS, INC. (TGTX) Q2 2026 10-Q on SEC EDGAR. USD.
TG THERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $240.3M, up $99.2M YoY from $141.1M, driven by BRIUMVI sales
- BRIUMVI U.S. product revenue $227.7M vs $138.8M YoY; ex-U.S. partner sales $8.1M
- Net income $7.8M vs $28.2M YoY; net margin 3.2% vs 20.0%
- Cash, equivalents and investments $612.3M at June 30; liquidity expected beyond twelve months
- Higher R&D and SG&A spending expected as clinical programs and commercialization expand
Risk Factors
- No material-change disclosure; carried-forward commercialization risk centered on BRIUMVI’s limited market acceptance and uncertain profitability
- Regulatory compliance risk from post-marketing studies, including long-term safety, pregnancy, and pediatric evaluations
- Competitive risk from larger biopharmaceutical companies with greater commercialization, regulatory, and capital resources
- Reimbursement risk from payor formularies, prior authorization, cost sharing, mandatory rebates, and potential MFN pricing
- Operational risk from reliance on third-party commercialization partners outside the U.S., including Neuraxpharm in Europe
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TG THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.